Real-World Validation of the Clinical Distinctiveness of IDH-Mutant Glioblastoma in the SEER Transition Era: A Population-Based Study Integrating Machine Learning.

Abstract excerpt

INTRODUCTION: The 2021 WHO classification reclassified "IDH-mutant glioblastoma (GBM)" as "Astrocytoma, IDH-mutant, grade 4." This study aims to provide real-world validation of this reclassification using the specific ICD-O-3 code (9445/3) from the Surveillance, Epidemiology, and End Results (SEER) "Transition Era" (2018-2022) and develop a machine learning (ML)-based prognostic model. METHODS: Patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Brain Neoplasms